THE IMC-1 PHASE 2B CLINICAL TRIAL

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Clinical medicine, Rheumatology, Fibromyalgia, Irritable bowel syndrome, IMC-1, the IMC-1 Phase 2b Clinical Trial, Virios Therapeutics, IMC-1, THE IMC-1 PHASE 2B CLINICAL TRIAL, VIRIOS THERAPEUTICS

We are excited about the FORTRESS trial as we are testing optimized doses of IMC-1, and we will be measuring patients fibromyalgia related pain on a daily basis.

Key Points: 
  • We are excited about the FORTRESS trial as we are testing optimized doses of IMC-1, and we will be measuring patients fibromyalgia related pain on a daily basis.
  • Based on industry standard fibromyalgia patient recruitment rates, we expect to complete the trial and announce top line results in mid-2022.
  • The dosing of the first patient in this Phase 2b trial marks an important milestone for Virios, as we develop new, combination antiviral therapies to improve care standards for patients suffering from chronic diseases like fibromyalgia and irritable bowel syndrome, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.
  • Virios Therapeutics is conducting FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1).